June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Effect of Anti-angiogenic Agents Targeting Integrins ανβ3 on human uveal melanoma and vascular endothelia
Author Affiliations & Notes
  • Hua Yang
    Ophthalmology, Emory University Eye Center, Atlanta, GA
  • Hans E Grossniklaus
    Ophthalmology, Emory University Eye Center, Atlanta, GA
  • Wayne Harris
    Hematology and Medical Oncology, Emory University, Atlanta, GA
  • Qing Zhang
    Ophthalmology, Emory University Eye Center, Atlanta, GA
  • Edmund K Waller
    Hematology and Medical Oncology, Emory University, Atlanta, GA
  • Ravi Chakra
    Biology, Georgia State University, Atlanta, GA
  • Zhi-Ren Liu
    Biology, Georgia State University, Atlanta, GA
  • Footnotes
    Commercial Relationships Hua Yang, None; Hans Grossniklaus, None; Wayne Harris, None; Qing Zhang, None; Edmund Waller, None; Ravi Chakra, None; Zhi-Ren Liu, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5324. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hua Yang, Hans E Grossniklaus, Wayne Harris, Qing Zhang, Edmund K Waller, Ravi Chakra, Zhi-Ren Liu; Effect of Anti-angiogenic Agents Targeting Integrins ανβ3 on human uveal melanoma and vascular endothelia. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5324.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Angiogenesis is a prerequisite for the growth and metastasis of solid tumors. Targeting the proliferation of tumor neovasculature will form an effective anti-cancer therapy. ProAgio is a noval anti-angiogenesis agent that targets Integrins ανβ3 of endothelial cells. In this study, we investigate the effect of the noval anti-angiogenesis agent on human uveal melanoma, mouse melanoma and human/mouse vascular endothelia cells, and screen the sensitivity of tumor cells for the further in vivo experiment.<br />

Methods: Primary human uveal melanoma cells Mel290, Mel270, OMM3, 02-1486, mouse melanoma Queens, mouse vascular endothelium sVEC and human vascular endothelium HUVEC were subcultured in 6-well-plates and treated with 5μm ProAgio or equal volume of PBS as control for 24 hours after more than 90% confluence. Harvested cells were stained with Caspase 3, CXCR4 and VEGFR2. The stained cells were acquired by FACScanto and analyzed by FlowJo software.<br />

Results: Comparing with the PBS control, ProAgio resulted in the elevated level of caspase 3 in vascular endothelia HUVEC and sVEC, the unchanged level of caspase 3 in human uveal melanoma and mouse melanoma cells. ProAgio decreased the level of CXCR4 in human uveal melanoma OMM3 and mouse vascular endothelium sVEC, also reduced the level of VEGFR2 in human uveal melanoma OMM3 and 02-1486, and vascular endothelia HUVEC, sVEC.<br />

Conclusions: ProAgio effectively caused the apoptosis in human and mouse vascular endothelia, not human uveal melanoma in vitro, suppressed the expression of VEGFR2 related with integrins ανβ3 and the migration indicator CXCR4 in vascular endothelia and some types of human uveal melanoma cells. We are able to select human uveal melanoma cells whose expressions of VEGFR2 and CXCR4 can be inhibited by ProAgio for the animal model, in purpose to know the effect of ProAgio on tumor growth and metastasis in vivo.<br />

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×